Study on Using AI Tools for Software Component Selection and Evaluation

Summary

We are conducting a study to understand how software professionals and academics use or perceive AI tools when choosing software components for projects. We want to learn about your experiences, challenges, and opinions on integrating AI into this process. Your insights will help us develop better tools and methods to improve software development practices.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 120

Accepts healthy participants: Yes

Inclusion criteria:

You may participate in this study if you:

1. Are 18 years of age or older.
2. Can read and write in English.
3. Are a software developer, software engineer, software architect, project manager, IT professional, or an academic researcher in software engineering.
4. Have at least one year of professional experience in software development or software engineering in industrial or academic environments.
5. Have experience selecting and integrating software components like libraries, modules, or services.

Exclusion criteria:

You are not eligible to participate if you:

1. Are under 18 years old.
2. Cannot read or write in English.
3. Do not have professional experience in software development or software engineering.

Participate

Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

If you are interested in participating in this study or have any questions, please feel free to reach out to us: Dr. Ann Barcomb (Principal Investigator) Email: ann.barcomb@ucalgary.ca Important Note: Privacy Consideration: If you wish to keep your employer or organization confidential, we recommend using a personal email address instead of a company email address when contacting us. This helps ensure your participation remains private and unassociated with your workplace. We look forward to hearing from you and appreciate your interest in our study!

Principal investigator:

Ann Barcomb

Clinical trial:

No

REB-ID:

REB21-1354